DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model.

DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model.

Pokaži ostale verzije (1)

Aims To explore the cost-effectiveness of alternative methods of screening family members for hypertrophic cardiomyopathy (HCM), the most common monogenic cardiac disorder and the most frequent cause of sudden cardiac death (SCD) in young people. Methods and results Economic decision model comparing...

Bibliografski detalji
Glavni autori:	Wordsworth, S, Leal, J, Blair, E, Legood, R, Thomson, K, Seller, A, Taylor, J, Watkins, H
Format:	Journal article
Jezik:	English
Izdano:	2010

Slični predmeti

Is DNA testing for hypertrophic cardiomyopathy cost-effective?
od: Wordsworth, S, i dr.
Izdano: (2006)

DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model
od: Wordsworth, S, i dr.
Izdano: (2010)

Evaluation of Clinical Diagnostic Potential of Next Generation Sequencing using Hypertrophic Cardiomyopathy as a Model
od: Taylor, J, i dr.
Izdano: (2010)

A fast-throughput service for Familial Hypertrophic and Dilated Cardiomyopathy using High resolution melt curve analysis on the Lightscanner
od: Thistleton, J, i dr.
Izdano: (2007)

Expansion of a diagnostic service for hypertrophic cardiomyopathy using next generation sequencing
od: Reid, S, i dr.
Izdano: (2011)

Linked genetic modifiers in hypertrophic cardiomyopathy
od: Ektisham, J, i dr.
Izdano: (2004)

Oxford Molecular Genetics Laboratory Cardiomyopathy Service
od: Thistleton, J, i dr.
Izdano: (2006)

Ascertainment strategies and genotype:phenotype correlations in hypertrophic cardiomyopathy.
od: Blair, E, i dr.
Izdano: (2003)

Hypertrophic cardiomyopathy:a paradigm for myocardial energy depletion.
od: Ashrafian, H, i dr.
Izdano: (2003)

Identification of a novel mitochondrial DNA mutation in the ND1 gene in 2 patients with hypertrophic cardiomyopathy with restrictive physiology
od: Khogali, S, i dr.
Izdano: (2001)

Early onset malignant hypertrophic cardiomyopathy caused by mutations in MYBPC3
od: Carballo, S, i dr.
Izdano: (2003)

Sudden death in hypertrophic cardiomyopathy.
od: Watkins, H
Izdano: (2000)

Myocardial dysfunction in hypertrophic cardiomyopathy.
od: Ashrafian, H, i dr.
Izdano: (2001)

Novel mutations in cardiac MYBPC3 and early onset malignant hypertrophic cardiomyopathy
od: Carballo, S, i dr.
Izdano: (2005)

Novel mutations in cardiac MYBPC3 causing early onset malignant hypertrophic cardiomyopathy
od: Carballo, S, i dr.
Izdano: (2005)

Hypertrophic cardiomyopathy in Noonan Syndrome closely mimics familial hypertrophic cardiomyopathy due to sarcomeric mutations.
od: Hudsmith, L, i dr.
Izdano: (2006)

Double mutations in CIS can confound genotype-phenotype correlations in hypertrophic cardiomyopathy
od: Blair, E, i dr.
Izdano: (2000)

Data-driven modelling of mutational hotspots and in silico predictors in hypertrophic cardiomyopathy
od: Waring, A, i dr.
Izdano: (2020)

Metabolic perturbations in the pathogenesis of hypertrophic cardiomyopathy
od: Ashrafian, H, i dr.
Izdano: (2005)

Eliciting expert opinion for economic models: an applied example.
od: Leal, J, i dr.
Izdano: (2007)

Novel mutations in cardiac MYPBC3 cause early onset malignant hypertrophic cardiomyopathy (HCM)
od: Carballo, S, i dr.
Izdano: (2005)

Mutations in cis can confound genotype-phenotype correlations in hypertrophic cardiomyopathy.
od: Blair, E, i dr.
Izdano: (2001)

The genetics of hypertrophic cardiomyopathy: Teare redux.
od: Watkins, H, i dr.
Izdano: (2008)

Experience in genetic testing of hypertrophic cardiomyopathy using nanopore DNA sequencing
od: R. R. Salakhov, i dr.
Izdano: (2021-11-01)

A novel mutation in phospholamban causes a mixed hypertrophic and dilated cardiomyopathy phenotype with autosomal dominant inheritance
od: Carballo, S, i dr.
Izdano: (2004)

Genetic clues to disease pathways in hypertrophic and dilated cardiomyopathies.
od: Watkins, H
Izdano: (2003)

Functional analysis of hypertrophic cardiomyopathy missense mutations in the light meromyosin region of beta myosin heavy chain
od: Redwood, C, i dr.
Izdano: (2003)

Identification of a novel mitochondrial NADH dehydrogenase I (MTND1) gene mutation in two patients with hypertrophic cardiomyopathy
od: Khogali, S, i dr.
Izdano: (2001)

Hypertrophic cardiomyopathy: from molecular and genetic mechanisms to clinical management
od: Watkins, H
Izdano: (2001)

Assigning a causal role to genetic variants in hypertrophic cardiomyopathy.
od: Watkins, H
Izdano: (2013)

Screening for hypertrophic cardiomyopathy: a cost analysis of echocardiography, cardiac magnetic resonance and genetic testing
od: Manning Warren J, i dr.
Izdano: (2009-01-01)

The prognostic impact of septal myectomy in obstructive hypertrophic cardiomyopathy.
od: Watkins, H, i dr.
Izdano: (2005)

Hypertrophic Cardiomyopathy
od: Asra K. Butt, i dr.
Izdano: (2023-03-01)

Disease pathways and novel therapeutic targets in hypertrophic cardiomyopathy.
od: Ashrafian, H, i dr.
Izdano: (2011)

Cardiac Steatosis Detected in Hypertrophic Cardiomyopathy, Dilated Cardiomyopathy and Aortic Stenosis
od: Suttie, J, i dr.
Izdano: (2011)

Private mitochondrial DNA variants in danish patients with hypertrophic cardiomyopathy.
od: Christian M Hagen, i dr.
Izdano: (2015-01-01)

Hypertrophic cardiomyopathy
od: Sarita Gore, i dr.
Izdano: (2022-01-01)

Hypertrophic Cardiomyopathy
od: Polakit Teekakirikul, MD, i dr.
Izdano: (2021-09-01)

Hypertrophic cardiomyopathy
od: Murillo de Oliveira Antunes, i dr.
Izdano: (2020-04-01)

The Role of Cardiopulmonary Exercise Testing in Hypertrophic Cardiomyopathy
od: Lidija Mikic, i dr.
Izdano: (2023-07-01)